Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹1,787.90
17.50 (0.99%)
High VOLATILITY
As on 10 Jul 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹45.36K Cr
MID CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
37.7
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹1,251.6+42.8%
52W High₹1,812.5-1.4%
Current Price
₹1,787.90
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹1,430.32
Upper Circuit₹2,145.48
Reference Price
₹1,787.90
Investment Checklist
Triple Bottom on 1W (BREAKOUT CONFIRMED) — target ₹1856.2
Inverse Head and Shoulders on 1W (BREAKOUT CONFIRMED) — target ₹1856.2
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Composite score 58.21 (STRONG_BUY) with 90.4% confidence
RSI at 71.5 — overbought, pullback risk
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Confidence
90%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
1694.2
EMA50
1627.89
EMA200
1509.27
Price Action
UPTREND
BULLISH
Higher Highs6
Higher Lows7
Lower Highs3
Lower Lows2
Support & Resistance Levels
Resistance (Above)
No recent resistance detected
Support (Below)
₹1674.15
₹1622.00
₹1588.80
₹1547.70
₹1530.00
Volume Analysis
TrendINCREASING
Change+131.40%
Unusual VolumeNo
Stop Loss Levels
Fixed Risk
1% Risk₹1770.02
3% Risk₹1734.26
5% Risk₹1698.51
7% Risk (Custom)
₹1662.75Technical Levels
1x ATR (Volatility)₹1735.88
2x ATR (Swing)₹1683.86
3x ATR (Trend)₹1631.84
Immediate Support₹1674.15
Moving Averages
EMA 9 (Short-term)₹1746.97
EMA 20 (Medium-term)₹1694.20
EMA 50 (Trend)₹1627.89
EMA 200 (Long-term)₹1509.27
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹2,161.7 Cr | ₹2,308.9 Cr | ₹2,556.5 Cr | ₹2,392.5 Cr |
| Net Profit | ₹67.8 Cr | ₹233.2 Cr | ₹282.6 Cr | ₹326.3 Cr |
| EPS | — | ₹9.19 | ₹11.14 | ₹12.86 |
| Operating Profit | ₹249 Cr | ₹449.1 Cr | ₹514.5 Cr | ₹571.2 Cr |
ROE
10.62%
ROCE
14.62%
Debt/Equity
0.20
Current Ratio
2.63
OPM
23.87%
NPM
13.64%
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| IPCA Laboratories Limited | ₹1,787.90 | +0.99% | 37.7 | ₹45.36K Cr mid Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 05 Aug 2025 | Dividend - Rs 2 Per Share | DIVIDEND |
| 27 Nov 2024 | Interim Dividend - Rs 2 Per Share | INTERIM_DIVIDEND |
| 06 Aug 2024 | Annual General Meeting/Dividend - Rs 2 Per Share | AGM |
| 22 Nov 2023 | Interim Dividend - Rs 2 Per Share | INTERIM_DIVIDEND |
| 22 Nov 2022 | Interim Dividend - Rs 4 Per Share | INTERIM_DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for IPCALAB
View AllNEWS
positive
Business Standard - Markets 16d ago
Ipca Laboratories Ltd spurts 0.16%, up for fifth straight session
Ipca Laboratories Ltd is quoting at Rs 1627.6, up 0.16% on the day as on 12:44 IST on the NSE. The stock is up 19.88% in last one year as compared to a 4.96% jump in NIFTY and a 15.12% jump in the Nifty Pharma.
AONELIQUIDAONENIFTYAONETMMQ50AONETOTALIPCALABPHARMABEESFinancial ServicesHealthcare
NEWS
positive
Business Standard - Markets 25d ago
Ipca Laboratories Ltd eases for fifth straight session
Ipca Laboratories Ltd is quoting at Rs 1575.6, down 0.47% on the day as on 13:19 IST on the NSE. The stock tumbled 15.63% in last one year as compared to a 4.2% slide in NIFTY and a 9.97% fall in the Nifty Pharma index.
AONELIQUIDAONENIFTYAONETMMQ50AONETOTALBANKIETFIPCALABPHARMABEESPVTBANIETFFinancial ServicesHealthcare
negative
CNBC TV18 - Markets 28d ago
Ipca Labs ties up with biotech firm to develop cancer and autoimmune disease treatments
Ipca Laboratories has signed a global licensing deal with BRL to develop and commercialise biologic therapies for cancer and autoimmune diseases.
GLOBALIPCALABConsumer ServicesHealthcare